bmn-673 and bosutinib

bmn-673 has been researched along with bosutinib* in 1 studies

Other Studies

1 other study(ies) available for bmn-673 and bosutinib

ArticleYear
UPLC-MS/MS method for the determination of talazoparib in rat plasma and its pharmacokinetic study.
    Journal of pharmaceutical and biomedical analysis, 2020, Jan-05, Volume: 177

    In the present study, an accurate and sensitive ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for the determination of plasma talazoparib concentration in rats was developed and established. The purpose of chromatographic separation of talazoparib and the internal standard (bosutinib) was achieved on an Acquity BEH C18 (2.1 mm × 50 mm, 1.7 μm) column with a flow rate of 0.40 mL/min, using a gradient elution with acetonitrile and 0.1% formic acid in water as the mobile phase. The detection was performed on a XEVO TQ-S triple quadrupole tandem mass spectrometer coupled with electrospray ionization interface under positive-ion multiple reaction monitoring (MRM) mode with the precursor-to-product ion transitions of m/z 381.3 → 285.2 for talazoparib and m/z 530.2 → 141.2 for bosutinib (IS), respectively. The method was linear over the range of 0.5-200 ng/mL for talazoparib. The accuracies and precisions of intra- and inter-day were all within the acceptance limits, and no matrix effect was observed in this method. The validated method was further employed to a pharmacokinetic study of talazoparib after oral treatment with 0.2 mg/kg talazoparib to rats.

    Topics: Administration, Oral; Aniline Compounds; Animals; Chromatography, High Pressure Liquid; Limit of Detection; Male; Models, Animal; Nitriles; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinolines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry

2020